Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Celgene's sNDA for Revlimid Gets Priority Review | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Celgene’s sNDA for Revlimid Gets Priority Review

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celgene Corp.’s sNDA for Revlimid, for the treatment of relapsed or refractory multiple myeloma, has been granted a Priority Review designation by the FDA. The company is seeking approval to market Revlimid in combination with dexamethasone as a proposed indication for the treatment of multiple myeloma patients who have received at least one prior therapy. Priority Review is granted to products that, if approved, would be a significant improvement compared to existing marketed products or therapies in the treatment, diagnosis, or prevention of a disease.

The sNDA submission is based on the safety and efficacy results of two large randomized Phase III special protocol assessment trials, North American Trial MM-009 and International Trial MM-010, evaluating Revlimid plus dexamethasone in multiple myeloma patients that have received at least one prior therapy. Based on a pre-specified interim analysis, both studies achieved the primary endpoint of time to disease progression (TTP) with combination therapy of lenalidomide and dexamethasone over that of placebo and dexamethasone.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters